Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CD38 | P28907 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30554614 | 1.00 | PARP1 (0.47) | PARP1LMNAGAAPTGS1CTSS | |
| Hydrochloric Acid SCHEMBL7069187 | 0.98 | PARP1 (0.46) | PARP1LMNAGAAPTGS1CTSS | |
| Acetic Acid SCHEMBL6002290 | 0.93 | PARP1 (0.43) | PARP1LMNAGAAPTGS1CTSS | |
| Trifluoroacetic Acid SCHEMBL4002171 | 0.93 | L3MBTL1 (0.43) | PARP1LMNAGAAPTGS1CTSS | |
| Succinic Acid SCHEMBL3925286 | 0.90 | AURKA (0.42) | PARP1LMNAGAAPTGS1AURKA | |
| SCHEMBL27722750 | 0.88 | PARP1 (0.49) | PARP1GAAAURKAKDM4EALDH1A1 | |
| SCHEMBL28322785 | 0.87 | LMNA (0.46) | PARP1LMNAGAAPTGS1CTSS | |
| Hydrochloric Acid SCHEMBL3705049 | 0.87 | PARP1 (0.44) | PARP1LMNAGAAPTGS1CTSS | |
| SCHEMBL2484728 | 0.84 | PARP1 (0.51) | PARP1LMNAGAAPTGS1AURKA | |
| SCHEMBL23041398 | 0.84 | LMNA (0.48) | LMNAGAAPTGS1CTSSALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3774773-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-02-17 | — | — | EP | claimed |
| WO-2019200161-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | DESIGN THERAPEUTICS INC. (US) | 2019-10-17 | — | — | WO | claimed |
| EP-3452460-A1 | HETEROARYL-1,2,4-TRIAZOLE AND HETEROARYL-TETRAZOLE COMPOUNDS FOR CONTROLLING ECTOPARASITES | Elanco Tiergesundheit AG (CH) | 2019-03-13 | — | — | EP | claimed |
| WO-2017192385-A1 | HETEROARYL-1,2,4-TRIAZOLE AND HETEROARYL-TETRAZOLE COMPOUNDS FOR CONTROLLING ECTOPARASITES | ELANCO TIERGESUNDHEIT AG (CH) | 2017-11-09 | — | — | WO | claimed |
| US-9382197-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2016-07-05 | — | — | US | claimed |
| WO-2008066890-A2 | POLYAMIDES WITH TAIL STRUCTURES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2008-06-05 | — | — | WO | claimed |
| WO-2006062478-A1 | NOVEL TREATMENT OF GASTROINTESTINAL DISORDERS | ASTRAZENECA AB (SE) | 2006-06-15 | — | — | WO | claimed |
| WO-2004087669-A1 | NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF | TAISHO PHARMACEUTICAL CO. LTD. (JP) | 2004-10-14 | — | — | WO | claimed |
| WO-2001021160-B1 | CARBOXYMIDE AND ANILINE DERIVATIVES AS SELECTIVE INHIBITORS OF PATHOGENS | AXXIMA PHARMACEUTICALS AG (DE) | 2002-05-30 | — | — | WO | claimed |
| EP-4727954-A1 | HEPARAN SULFATE GLYCOMIMETIC COMPOUNDS, THEIR USES AND INTERMEDIATES FOR THEIR PREPARATION | Victoria Link Limited (NZ) | 2026-04-22 | — | — | EP | disclosed |
| US-12583851-B2 | Heteroaryl-substituted pyrazine derivatives as pesticides | ELANCO ANIMAL HEALTH GMBH (DE) | 2026-03-24 | — | — | US | disclosed |
| WO-2024258295-A1 | HEPARAN SULFATE GLYCOMIMETIC COMPOUNDS, THEIR USES AND INTERMEDIATES FOR THEIR PREPARATION | DEVLIN RORY GERARD (NZ) | 2024-12-19 | — | — | WO | disclosed |
| EP-4392408-A1 | PYRAZINE COMPOUNDS FOR THE CONTROL OF INVERTEBRATE PESTS | BASF SE (DE) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024123815-A1 | PROCESS FOR THE SYNTHESIS OF SUBSTITUTED TETRAHYDROFURAN MODULATORS OF SODIUM CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-06-13 | — | — | WO | disclosed |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
| US-6821964-B2 | FOR PROPHYLAXIS AND THERAPY OF DISEASES ASSOCIATED WITH MONOCYTE ACCUMULATION, LYMPHOCYTE ACCUMULATION OR LEUCOCYTE ACCUMULATION | PFIZER INC | 2004-11-23 | — | — | US | disclosed |
| US-6506951-B1 | Process for producing brominated trifluoromethylbenzenes | CENTRAL GLASS COMPANY, LIMITED (JP) | 2003-01-14 | — | — | US | disclosed |
| US-6326517-B1 | REACTIN AN AROMATIC COMPOUND WITH CARBON MONOXIDE AND AMMONIA | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-04 | — | — | US | disclosed |
| EP-0888336-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)P IPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1999-01-07 | — | — | EP | disclosed |
| WO-1997030989-A1 | NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDIN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12583851-B2 | Heteroaryl-substituted pyrazine derivatives as pesticides | CBR3, CYCS, CWC15 | PARP1 4707/4885LMNA 2168/4885GAA 4709/4885 |
| US-20050054627-A1 | Cyclic derivatives as modulators of chemokine receptor activity | CCL11, CCL2, CCR1 | PARP1 2802/4885LMNA 4468/4885GAA 4545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.